Lexicon Pharmaceuticals | LXRX - Loan Capital


Lexicon Pharmaceuticals reported $49.41M in Loan Capital for its fiscal quarter ending in December of 2025.





Loan Capital Change Date
Abbott USD 9.9B 1.7B Dec/2025
Acadia Pharmaceuticals USD 0 0 Mar/2025
Agios Pharmaceuticals USD 1.06M 0 Sep/2022
Akebia Therapeutics USD 48.25M 609K Dec/2025
Alnylam Pharmaceuticals USD 2.48B 1.44B Dec/2025
AstraZeneca USD 26.14B 19.58B Dec/2025
BioMarin Pharmaceutical USD 597.18M 513K Dec/2025
Coherus Biosciences USD 51.08M 496K Dec/2025
Eli Lilly USD 40.87B 5.6M Dec/2025
Esperion Therapeutics USD 457.65M 9.5M Dec/2025
Halozyme Therapeutics USD 2.14B 1.34B Dec/2025
Illumina USD 1.49B 496M Dec/2025
Insmed USD 540.96M 1.24M Dec/2025
Ironwood Pharmaceuticals USD 583.99M 14.83M Dec/2024
J&J USD 39.44B 30M Dec/2025
Lexicon Pharmaceuticals USD 49.41M 7.1M Dec/2025
MacroGenics USD 70M 256K Dec/2025
MannKind USD 548.44M 244.79M Dec/2025
Merck USD 39.97B 6B Sep/2025
Moderna USD 610M 584M Dec/2025
Novartis USD 29.59B 5.35B Dec/2025
PTC Therapeutics USD 2.03B 193.22M Dec/2025
Puma Biotechnology USD 10.87M 222K Jun/2025
Sarepta Therapeutics USD 828.97M 206.17M Dec/2025
Thermo Fisher Scientific USD 35.85B 4B Dec/2025
Ultragenyx Pharmaceutical USD 763.74M 19.02M Sep/2025
United Therapeutics USD 100M 100M Jun/2024
Vanda Pharmaceuticals USD 3.15M 3.15M Dec/2024